FDA Track Record In Risk Communication Raised As Key Sentinel Concern
Executive Summary
FDA's ongoing challenges with effectively communicating the risks indicated by postmarket safety signals need to be resolved before the agency activates its Sentinel surveillance program, a number of participants said during a Dec. 16 FDA workshop